October 21st 2024
Research shows that after 60 months of treatment, 38% of patients achieved complete remission.
September 10th 2024
Increased Risk of Rosacea Found in Former Smokers, But Connection is Hazy in Current Smokers
August 19th 2024People affected by rosacea can experience symptoms such as facial redness, flushing, and visible blood vessels. At times, they may also develop pimples or thickened skin, especially around the nose
Read More
Ruxolitinib Cream Proves Safe for Young Children with Atopic Dermatitis
July 22nd 2024These results were found in the TRuE-AD3 study that was presented at the Society for Pediatric Dermatology meeting earlier this month, revealing the latest round of data collected in the TRuE-AD1 and TRuE-AD2 series of studies.
Read More
Study Reveals Severe Impact of Atopic Dermatitis on Women's Quality of Life and Reproductive Health
July 15th 2024Although AD is a common condition, it’s impact on sexual function and reproductive health is not well understood. In addition, many women with AD are undertreated during pregnancy due to concerns about medication side effects.
Read More
High Sodium Intake Associated to Increased Risk of Severe Atopic Dermatitis
June 20th 2024Researchers who conducted the study, of the Universities of California in San Francisco and Berkley, suggest that cutting down on sodium could be a more cost-effective and low-risk way to help manage AD.
Read More
Highly Contagious and Hard-to-Treat Fungal Skin Infections Are Emerging, Experts Warn
June 6th 2024Experts are urging healthcare providers to be aware of these two new forms of ringworm or jock itch, known as Trichophyton mentagrophytes type VII (TMVII) and Trichophyton indotineae or T. indotineae.
Read More
Joseph Zabinski Advocates for Patient Trust in AI Adoption in Dermatology Care
April 18th 2024Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
Read More
Microneedling Combined with Other Vitiligo Therapies Offers Promising Treatment for Skin Disease
April 10th 2024Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Read More
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
Opzelura Provides Benefit in Atopic Dermatitis in Real-World Studies | AAD 2024
March 8th 2024Physicians switch to Opzelura (ruxolitinib) when other therapies fail to help patients with atopic dermatitis, according to a new analysis presented at the annual meeting of the American Academy of Dermatology.
Read More
Reasons for attending the AAD meeting | AAD 2024
March 7th 2024John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.
Read More
FDA Approves First-in-Class Cell Treatment for Patients With Advanced Melanoma
February 19th 2024Amtagvi was approved to treat patients with advanced melanoma. It is a one-time cell therapy that will be administered at authorized treatment centers and have a wholesale acquisition cost of $515,000.
Read More
New AAD Acne Guidelines Warn About High Cost, Access to New Treatments
February 6th 2024New acne guidelines from the American Academy of Dermatology recommend Winlevi (clascoterone), a topical treatment, and Seysara (sarecycline), a narrow-spectrum tetracycline, but qualify the recommendation as conditional because of concerns that the high cost may affect equitable access to treatment,
Read More
Study Examines the Correlation Between COVID-19 Vaccination and Vitiligo Onset
January 24th 2024A recent study presents a unique case of sudden-onset vitiligo following the COVID-19 vaccination, along with a systematic review of existing literature to shed light on the potential link between vaccination and vitiligo development.
Read More